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Abstract
The hepatitis B virus nucleocapsid or core antigen is extremely immunogenic during infection and after immunization. This review
summarizes several features of the nucleocapsid which explain this exceptionally high immunogenicity: a unique three-dimensional folding,
the presence of a region that interacts with immunoglobulins outside the classical antibody-binding site, the presence of many CD4+ T cell
epitopes, and the presence of encapsidated nucleic acids. Because of these features, nucleocapsids efficiently interact and activate antigen
presenting cells, especially naı¨ve B cells. This leads to the generation of a dominant Th1 immunity phenotype and the secretion of high
levels of IgM and IgG anti-nucleocapsid antibodies.
© 2003 Elsevier B.V. All rights reserved.
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1. Introduction
Infections with the hepatitis B virus (HBV) remain a ma-
jor cause of morbidity and mortality worldwide. More than
2 billion people alive today have been infected by HBV and
over 350 million people remain chronically infected. The
clinical manifestations of HBV infection are highly poly-
morphic, ranging from inapparent forms to fulminant hep-
atitis, acute self-limited hepatitis, chronic hepatitis, cirrho-
sis, and hepatocellular carcinoma (HCC). HBV is transmit-
ted sexually, parenterally, and from mother to infant in the
perinatal period. Most adult onset HBV infections resolve,
presumably due to the polyclonal, multi-specific immune re-
sponses that the patients mount against the viral proteins.
Approximately 5–10% of acutely infected adults become
persistently infected by the virus. However, perinatal HBV
infections are rarely cleared in that over 90% of infected
children develop chronic infections.
HBV is the prototype of a family of viruses, referred
to as Hepadnaviridae. It is the smallest animal DNA virus
known. The genome consists of about 3200 nucleotides
and is a partially double-stranded relaxed circular DNA
molecule. Four open reading frames—the polymerase (P)
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gene, the X gene, the precore/core (preC/C) gene, and the
surface (preS/S) gene—have been identified which encode
seven proteins. Four major viral RNA molecules are found
in infected cells. The pregenomic RNA, which serves as the
template for viral DNA formation, additionally serves as the
mRNA for the viral polymerase (P) and the core proteins
(HBcAg and HBeAg). The preS/L-mRNA is the template
for the translation of the membrane proteins M and L,
which have 226 carboxy-terminal amino acids in common
with the S protein. This membrane protein is translated
from the S-mRNA. From the X-mRNA, the X protein is
translated. The P protein, HBcAg and the membrane pro-
teins S, M, and L are structural proteins. HBcAg monomers
assemble into a capsid structure, which encapsidates prege-
nomic RNA together with the P protein. This pregenomic
RNA is reverse transcribed into DNA, an event that occurs
within the infected cell. These nucleocapsids interact with
cytosolically exposed regions of the L protein present in the
endoplasmic reticulum-to-Golgi intermediate compartment,
into which viruses bud (Seeger and Mason, 2000). Besides
infectious virions, also called Dane particles, infected hepa-
tocytes produce nucleocapsid-free particles, termed HBsAg.
These can accumulate to several hundred micrograms per
milliliter in the blood. The function of these particles is
unclear (Vanlandschoot and Leroux-Roels, 2003). A sec-
ond secreted monomeric viral protein is HBeAg. Mature
HBeAg is a 16 kDa secreted, processed, and non-particulate
form of HBcAg that is truncated at the C-terminus at amino
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acid position 149 (Takahashi et al., 1983) while it retains
an additional 10 precore amino acids at its N-terminus
(Standring et al., 1988). As for HBsAg, the role during in-
fection of HBeAg and the X protein remains largely unclear
(Milich et al., 1990; Staib et al., 2003). Recently, two novel
proteins were reported, which are translated from alterna-
tively spliced RNAs (Soussan et al., 2000; Huang et al.,
2000).
During HBV infection, at least four antigen–antibody
systems are observed: (1) HBsAg and anti-HBsAg; (2) preS
antigen and anti-preS antibody; (3) HBcAg and anti-HBcAg;
and (4) HBeAg and anti-HBeAg. These serological markers
are used to demonstrate HBV infection and to discriminate
acutely from chronically infected patients. The appearance
of the anti-envelope antibody in the naturally infected sub-
ject, although it is often delayed, indicates the elimination
of virus and recovery. Usually, anti-HBsAg is readily de-
tectable in the patients who successfully clear the virus, but
not in the chronic patients. Seroconversion from HBeAg
to anti-HBeAg occurs later in the course of the infec-
tion and its appearance usually correlates with elimination
of virus.
Remarkably, HBcAg seems significantly more immuno-
genic than the envelope proteins and HBeAg. High titers
of anti-HBcAg are produced by virtually all HBV-infected
patients. IgM anti-HBcAg appears early in acute hepatitis
B, and IgG anti-HBcAg can persist with slowly decreas-
ing titers for many years, and even for life. Many studies
have shown that during chronic HBV infection, the titer of
IgM anti-HBcAg may fluctuate considerably in relation to
clinical reactivation and may be useful to monitor antiviral
therapy (Sjogren and Hoofnagle, 1985; Surrenti et al., 1986;
Gerlich et al., 1986; Koike et al., 1987; Smith et al., 1992;
Colloredo Mels et al., 1993; Brunetto et al., 1993). The
presence of IgM anti-HBcAg correlated with persistent viral
replication and could generally be used as an indicator for
acute exacerbation in chronic patients. The significance of
IgM anti-HBcAg has been further clarified by Marinos et al.
(1994), who showed that serum IgM anti-HBcAg strongly
correlated with hepatocellular damage immunopathologi-
cally related to HBV infection in patients. This study also
showed that the IgM anti-HBcAg index value also corre-
lated well with the degree of hepatocellular lysis (AST) but
not with HBV replication (HBV-DNA).
HBcAg and HBeAg share most of their sequence (149
amino acid homology) and are highly cross-reactive at the T
cell level (Milich et al., 1987, 1988). Nevertheless, HBcAg
and HBeAg are recognized differently by B cells and the im-
mune response towards both antigens appears to be regulated
independently. This observation has raised a lot of interest
and extensive research suggests that this higher immuno-
genicity of HBcAg is a consequence of several characteris-
tics: a unique three-dimensional folding, the presence of a
region that interacts with immunoglobulins outside the clas-
sical antibody-binding site, the presence of many CD4+ T
cell epitopes, and the presence of encapsidated nucleic acids.
2. Structural characteristics of the capsid protein
HBcAg
The nucleotide sequence of the HBV core protein en-
codes a single polypeptide of 183 amino acids (21 kDa)
that assembles to form nucleocapsid particles. The nucleo-
capsid of HBV is a 30–32 nm particle. The HBcAg protein
of HBV consists of two domains: the assembly domain
(amino acids (aa) 1–149) that forms the contiguous spher-
ical shell, and the protamine domain (aa 150–183) that
is responsible for RNA packaging (Petit and Pillot, 1985;
Nassal, 1992). When the protamine domain is removed, the
core protein still assembles into shells and is practically
indistinguishable from full-length capsid particles using
electron cryomicroscopy, provided the truncation point is
not before amino acid 140. However, it no longer packages
nucleic acid (Gallina et al., 1989; Birnbaum and Nassal,
1990). Previous study (Wingfield et al., 1995) on the sec-
ondary structure of HBV capsid protein with far-UV circu-
lar dichroism (CD) indicated that HBcAg is predominantly
(43–60%) -helical and has a low content of -sheet. Re-
cently, X-ray and electron cryomicroscopy studies (Conway
et al., 1997; Bottcher et al., 1997; Wynne et al., 1999) (see
Fig. 1) have further shown that the structure of HBV cap-
sid protein is largely -helical, and dominated by a long
-helical hairpin consisting of residues 50–73 (3) and
79–110 (4). The N-terminal region (aa 1–12) adopts an ir-
regular structure, followed by a short helix, 1 (aa 13–17),
and a long helix, 2 (aa 27–43), which together surround
three sides of the -helical hairpin. The C-terminal re-
gion consists of 5 (aa 112–127) followed by an irregular
proline-rich loop (aa 128–136) and an extended strand (aa
137–143). The conserved hydrophobic core is responsible
for the stabilization of the monomer fold.
Two monomers of HBV polypeptide associate to form
a compact dimer by homologous intermolecular disulfide
bridges (Bottcher et al., 1997; Wynne et al., 1999). HBcAg
contains four cysteine residues at positions 48, 61, 107, and
183. Studies (Zheng et al., 1992; Nassal et al., 1992) us-
ing site-directed cysteine mutation showed that all mutants
assemble into essentially identical core particle structures,
suggesting that disulfide bonds are not essential for core par-
ticle formation. Indeed, disulfide bridges are not found in
intracellular capsids and the extracellular formation of the
disulfide bridges can be enhanced by Cu2+ (Nassal et al.,
1992). No intra-chain disulfide bonds occur. Cys61, located
at the dimer interface, is always and Cys48 is partly in-
volved in inter-chain disulfide bonds with identical residues
of another monomer. Cys107 is a free thiol buried within
the particle structure, whereas Cys183 is always involved in
a disulfide bond with the Cys183 of the partner monomer.
HBcAg proteins are able to assemble into two particle
sizes, large (34 nm) and small (30 nm), composed of 240 and
180 subunits, which corresponded to triangulation number
T = 4 and T = 3 dimer clustered packings. The subunits
are clustered as dimers (120 or 90), producing the spikes
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Fig. 1. Structure of the HBV capsid monomer derived from the crystal structure (left), the capsid dimer (middle), and the capsid (right). Source: Wynne
et al., 1999.
that stick out from the underlying shell domain. The dimer
clustering of subunits produces spikes on the surface of the
shell, which consist of radial bundles of four long -helices
(Bottcher et al., 1997; Conway et al., 1997). Each HBcAg
monomer participates in helical bundle formation by an an-
tiparallel -helical hairpin about 42 Å in length. Most of the
monomer–monomer interface within the dimer consists of
interactions between the two homologous straight -helices
in the two opposed hairpins (Bottcher et al., 1997; Conway
et al., 1997). The capsid is fenestrated, with large pores with
a diameter of 12–15 Å. It has been proposed that these pores
are essential to allow nucleotides access to the capsid inte-
rior during the DNA synthesis and it is also relevant to the
reported accessibility of the C-terminal tail to proteinases
and antibodies (Machida et al., 1991; Wynne et al., 1999).
When the C-terminal region is replaced by foreign inserted
sequences, these insertions can be detected by special an-
tibodies on the outside of the assembled capsids (Borisova
et al., 1989).
3. The immunogenic structure of HBcAg
3.1. Human CD4+ T cell recognition sites
HBcAg contains numerous T cell recognition sites. In
one study (Ferrari et al., 1991), where a series of synthetic
peptides covering the HBcAg molecule was used to ana-
lyze the T cell recognition of HBcAg, amino acid sequence
(aa 50–69) was found to be the dominant T cell epitope in
man. A significant proportion of T cells from different HBV
patients was also able to respond to two additional pep-
tides corresponding to amino acids 1–20 and 117–131 of the
HBcAg (Ferrari et al., 1991). Another group revealed addi-
tional predominant T cell recognition sites within HBcAg
molecule, namely amino acids 1–25 and amino acids 61–85
(Jung et al., 1995). Importantly, two immunodominant T cell
epitopes (aa 1–20 and 50–69 or 1–25 and 61–85) within
HBcAg were found to induce significant T cell responses in
a large proportion of patients (Ferrari et al., 1991; Jung et al.,
1995) irrespectively of their HLA haplotype. In addition to
these major epitopes, minor T cell epitopes within HBcAg
have been identified, such as amino acids 20–34, 28–47,
70–89, 82–101, 100–119, 140–155, and 169–183 (Ferrari
et al., 1991; Cao et al., 2002).
HBcAg-specific T cells from a variety of inbred mouse
strains recognize multiple but distinct sites within the
HBcAg/HBeAg sequences. Each mouse strain recognizes
a predominant T cell determinant and the specificity of
this recognition is dependent on the H-2 haplotype of the
responding strain (Milich et al., 1987).
3.2. Human CD8+ T cell recognition sites
So far, only one HLA-A2-restricted epitope (aa 18–27)
has been identified in the HBcAg/HBeAg, whereas more
CTL sites within envelope and polymerase proteins were
found. Additional CTL nucleocapsid epitopes located at
HBcAg residues (aa 141–151) were defined (Missale et al.,
1993). The CTL response to this epitope is dually restricted
by the HLA-A31 and HLA-Aw68 alleles. Another naturally
processed HBcAg peptide (aa 88–96) was identified and rec-
ognized by HLA-A11-restricted CD8+ CTLs (Tsai et al.,
1996).
3.3. B cell recognition sites
The analysis of B cell recognition sites within core par-
ticle has revealed, so far, only one major conformational
antigenic determinant which was located around amino acid
position 80 (aa 74–83) (Salfeld et al., 1989). Another B
cell epitope located around portion (aa 107–118) has been
reported by others (Colucci et al., 1988). The dependence
of HBcAg antigenicity on conformational integrity suggests
that linear peptides may not be sufficient to mimic HBcAg
B cell epitopes completely. This is strongly supported by re-
4 P. Vanlandschoot et al. / Antiviral Research xxx (2003) xxx–xxx
cent findings on the structure of core particle. The sequence
78–82 corresponding to the immunodominant region of the
core protein lies at the tip of the spike. Recently, using cry-
omicroscopy and a monoclonal antibody that recognizes the
peptide from residues 78 to 83, Conway et al. (1998) have
shown that this epitope (78–83) resides on the outer rim of
the 30 Å long spikes. In addition to the major immunodom-
inant region, another epitope in the region of amino acid
130 has been identified (Salfeld et al., 1989). This region
lies at the end of the C-terminal helix, forming a loop that
is exposed and makes a small protrusion on the surface of
the shell. This protrusion provides the next most exposed
and accessible feature on the surface. The monoclonal anti-
bodies against this region (aa 127–133) label well-preserved
shells (Pushko et al., 1994).
4. The immunogenicity of capsids in mice and man
In 1986, Milich and McLachlan reported that the nucleo-
capsid is both a T cell-independent and a T cell-dependent
antigen. In euthymic mice, a single injection of capsids
stimulated IgM and IgG antibodies and helper T cell func-
tion. When capsids were injected into athymic (nude) mice,
which do not have T cells, capsids still induced IgM and
IgG class antibodies. This T cell-independent induction
of antibodies was lost when capsids were denatured. Nev-
ertheless, both intact and denatured capsids were highly
cross-reactive at the T cell level. Following these obser-
vations, capsids proved more immunogenic in terms of
antibody production as compared to HBeAg. Again capsids
and HBeAg were equally immunogenic and cross-reactive
at the T cell level (Milich et al., 1988). These experiments
were performed using Freund’s complete or incomplete ad-
juvant, but capsids turned out to be very immunogenic even
in the absence of adjuvant. Immunizations with as little as
6 ng of capsids in saline resulted in detectable anti-HBcAg
production 2 weeks after a single injection. Furthermore,
capsids elicited primarily IgG2a and IgG2b antibodies,
with low level of IgG3 and no IgG1 antibodies. Such a
response is indicative for a dominant Th1-like phenotype.
In contrast, HBeAg which is highly cross-reactive at the
T cell level induced primarily IgG1 antibodies, indicative
for a Th2-like phenotype. Cytokine production by capsid
and HBeAg-primed Th cells confirmed this Th1 or Th2
phenotype: capsid-primed T cells efficiently produced IL-2
and IFN- but low levels of Il-4. HBeAg-primed T cells
efficiently produced Il-4 and low levels of IFN-. The use
of incomplete Freund’s adjuvant increased the antibody re-
sponse, but did not alter the IgG isotype profile. In athymic
mice, the T cell-independent anti-capsid response was char-
acterized by efficient IgG2b and IgG3 isotype production
and virtually no IgG1 and IgG2a (Milich and McLachlan,
1986; Milich et al., 1997b).
From these and additional experiments, it was concluded
that the structural form of the capsids was the determin-
ing factor in the outcome of Th phenotype. Moreover, the
structure of the capsids was considered to be directly re-
sponsible for the T cell-independent induction of IgM and
IgG in mice and more importantly during HBV infection in
humans. However, all the evidences for the unique quality
of capsids was generated in mice, which is not a natural
host of HBV. Because experiments with humans are limited
and in order to examine the immunogenicity of capsids for
human lymphoid cells, a human peripheral blood leukocyte
(hu-PBL)-NOD/severe combined immunodeficient (Scid)
mouse model was developed. The ability of Scid mice to
accept xenografts has been utilized in different research
fields as a laboratory model to study the human immune
system (Mosier, 1991; Tary-Lehmann et al., 1995). In
most models, hu-PBL were injected into the peritoneal
cavities of recipient mice, leading to a rapid and predom-
inant expansion of T cells. Recently, we discovered that
transfer of hu-PBL directly into the spleens of NOD/Scid
mice, irradiated and treated with an antibody that reduces
mouse natural killer cells, led to a vigorous expansion of
B cells and their differentiation into plasmacytoid cells
(Depraetere et al., 2001). Using this model, we showed
that HBV capsids induced the production of capsid-binding
IgM molecules when PBL of unprimed individuals together
with capsids were transferred into NOD/Scid recipient
mice. This was observed with adult human and neonatal
(cord blood) donors. In addition, capsids activated purified
human B cells to produce IgM anti-capsid in the chimeric
mice, thus providing evidence that capsids behave as a T
cell-independent antigen in humans. However, a switch
from IgM to IgG production could not be induced, not
even after a booster injection with capsids in vivo. How-
ever, capsid-specific IgG was readily detected when PBL
were used from subjects who had recovered from an acute
HBV infection or who still had an ongoing chronic HBV
infection. From these observations, it was concluded that
the nucleocapsid is both a T cell-independent and a T
cell-dependent antigen in humans as in mice (Cao et al.,
2001).
5. What determines this high immunogenicity of the
capsid?
Milich and McLachlan in 1986 hypothesized that a
unique structural folding of the capsid was the underlying
determinant for its high immunogenicity. They further sug-
gested that capsids were able to directly activate B cells to
produce antibodies to the core in the presence or absence of
HBcAg- or HBeAg-sensitized T cells. When the structure
of the capsid was revealed by electron cryomicroscopy it
was proposed that the orientation of the dimeric spikes dis-
tributed over the surface of the capsid shell might be optimal
for cross-linking B cell membrane Ig antigen receptors. The
position of the dominant B cell epitope on the tip of the
spikes was very provocative in this respect. Based on this
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hypothesis, Milich et al. (1997) showed that spleen cells
from naı¨ve mice were able to activate HBcAg-specific T
cell hybridomas very efficiently when using capsids but not
with HBeAg. Depletion of the B cells abolished this capac-
ity of capsids to efficiently activate the HBcAg-specific T
cell hybridomas. In contrast, purified B cells preferentially
presented capsids as compared with HBeAg. The role of B
cells in the activation of HBcAg-specific T cell hybridomas
was further substantiated using spleen cells from B cell neg-
ative “knockout” (MT) mice. Antibodies directed against
mouse Ig significantly inhibited B cell presentation of cap-
sids and not of a HBcAg-derived peptide to T cell hybrido-
mas. Similarly, capsid-specific antibodies inhibited B cell
presentation of capsids. These observations demonstrated
that only capsid-specific B cells function as antigen pre-
senting cells and that capsids do not behave like superanti-
gens. Capsids were capable of inducing the co-stimulatory
molecules CD80 and CD86 on purified resting B cells. Since
similar results were obtained using resting B cells from
LPS-non-responsive C3H/HeJ mice, it is very unlikely that
the immunostimulatory qualities of the capsids were due to
possible endotoxin contaminants. Naı¨ve B cells produced
capsid-binding IgM, when co-cultured with very low levels
of capsids and T cells from HBcAg- or HBeAg-specific
T cell receptor transgenic mice (Lazdina et al., 2001).
Finally, it was demonstrated that B cells can function
as antigen presenting cells in mice (Milich et al., 1997).
Using three different methods to quantify capsid-binding
B cells, their frequency in the spleen of naı¨ve mice was
estimated to be in the range of 4–8% (Lazdina et al.,
2001).
Based on these observations, it was predicted that naı¨ve
B cells that bind and present HBV capsids have Ig sur-
face receptors with a common motif or a restricted usage
of variable heavy (VH) and light chain (VL) coding genes.
Cloning and sequencing of the VH and VL domains of
seven IgM secreting hybridomas revealed that six were re-
lated to human and murine VH1 germ line gene families;
one was related to the murine VH3 family. A linear motif
that binds HBcAg was identified in the framework region
1-complementarity-determining region 1 (FR1-CDR1) junc-
tion of these genes. This motif was either present in heavy
chains of the mouse VH1 family or in the light chain of the
mouse VH3 family. Peptides, homologous to the FR1-CDR1
junctions of human VH1 and VH7 germ lines were shown
to bind to HBcAg (Lazdina et al., 2001). The binding site
on the capsids was subsequently shown to involve residues
76–80, which lie on the tip of the spikes and are part of the
immunodominant epitope (Lazdina et al., 2003).
From these observations it is very clear that the high hu-
moral immunogenicity of HBV capsids is determined by
its capacity to interact with B cells. However, it remains
unclear why this interaction would skew the immune re-
sponse towards a Th1 phenotype. Oligonucleotides (ODN)
with immunostimulating sequences are potent activators of
the innate and adaptive immune system. Mixed with protein
they prime a Th1 immunity and CTL activity (18–26). Cap-
sids expressed in bacteria, yeast, or mammalian cells and
made of full-length core proteins always contain RNA, ap-
proximately 5–20 ng/ug varying in length from 30 to 3000
nucleotides (Birnbaum and Nassal, 1990). Based on these
observations, Schirmbeck and colleagues investigated if the
encapsidated RNA was critical for Th1 priming. Deletion of
the C-terminal arginine-rich end generates capsids in which
>98% of RNA binding is lost. Immunization of mice with
such truncated capsids no longer primed a Th1 immune re-
sponse, but a clear Th2 response. Immunization of mice with
full-length capsids induced primarily IgG2a isotype antibod-
ies and secretion of high levels of IFN- by CD4+ T cells,
while primarily IgG1 and low levels of IFN- were observed
when using truncated capsids. Interestingly, non-immune
cells and bone marrow-derived dendritic cells stimulated
with full-length capsids produced IL-12 p70. Capsids treated
with SDS, which results in loss of encapsidated RNA, no
longer induced this Th1 phenotype, indicating that the low
amounts of RNA in the capsids are required for priming
Th1 immunity. Codelivery of RNA with HBeAg resulted in
a more Th1 biased immunity instead of a Th2 immune re-
sponse. However, 1000-fold higher doses of RNA had to be
used compared to the small amounts of RNA associated with
full-length capsids. Intradermal delivery with the gene gun
always primes a Th2 immune response. Interestingly, using
this gene gun it was demonstrated that intradermal immu-
nization of mice with full-length capsids, resulted in a mixed
Th1/Th2 immunity. Gene gun immunization with truncated
capsids resulted in a clear Th2 immunity (Riedl et al., 2002).
Based on these observations, Schirmbeck and colleagues
suggested that trace amounts of prokaryotic or eukaryotic
RNA have a potent enhancing and modulating effect on
the immune response towards the capsids. They proposed
that the particle-associated delivery is a key factor for this
adjuvant effect of the RNA. The RNA is protected from
degradation by nucleases during its extracellular phase and
during uptake by cells. Following uptake of capsids by en-
docytosis or macropinocytosis, particles would be disrupted
in an acid late endosomal or early lysosomal compartment.
Uptake of one capsid delivers 180–240 copies of a single
protein into the antigen-processing and -presenting cell. In
the same compartment the encapsidated RNA would proba-
bly be released, allowing it to interact with immunostimula-
tory receptors. For immune stimulating ODN it has indeed
been demonstrated that their adjuvant effect requires the
uptake into an acidic compartment (Yi et al., 1998; Hemmi
et al., 2000), where they bind to toll-like receptor 9, trig-
gering signal transduction by MyD88, MAP kinases, and
NFB. Toll-like receptor 3 has been demonstrated to bind
double-stranded RNA and to activate MyD88, MAP ki-
nases, and NFB (Alexopoulou et al., 2001; Matsumoto
et al., 2002). A similar interaction of capsid-derived
RNA with toll-like receptor 3 in endosomes could ex-
plain the intrinsic adjuvant effect of HBV capsids (see
Fig. 2)
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Fig. 2. Schematic representation of the proposed different immune response pathways triggered by the HBV nucleocapsid. Pathway 1 (T cell-independent
pathway): Binding of RNA-containing nucleocapsids (green) leads to T cell-independent secretion of IgM, IgG2b/3, and in the induction of Th1 cells
and CTLs. Pathway 2: Following binding and uptake of nucleocapsids by naı¨ve B cells, the interaction between these B cells and T cells results in the
T cell-dependent secretion of IgG2a and IgG2b. Pathway 3: The uptake of RNA-containing nucleocapsids leads to activation of antigen presenting cells
(dendritic cells), secretion of IL-12, and generation of Th1 cells. These enhance the secretion of IgG2a and IgG2b isotype antibodies. Pathways 4 and
5: Binding of truncated capsids, denatured capsids or HBeAg (red) to B cells, together with uptake by antigen presenting cells, results in induction of
Th2 cells and secretion of IgG1 isotype antibodies.
6. Concluding remarks
Crucial for the exceptional high humoral and Th1 im-
munogenicity of the HBV nucleocapsid is the presence in
its primary sequence of potent T helper epitopes, the proper
spacing between the repetitive tips and the presence of en-
capsidated RNA. The ability of capsids to bind and acti-
vate a high frequency of naı¨ve B cells is probably mediated
through binding of the tip of the repetitive spikes to a linear
motif present in the FR1-CDR1 junction of the heavy and
light chain of surface immunoglobulins. Following binding,
the cross-linking of Ig membrane receptors results in intra-
cellular signaling, secretion of IgM and IgG anti-HBcAg,
and upregulation of co-stimulatory molecules. Capsids are
taken up and capsid-derived T cell epitopes, which are abun-
dant in the core protein, are presented to naı¨ve T helper cells.
The interaction between the activated B cells and T cells
subsequently is thought to result in the development of a
Th1 helper phenotype, followed by enhanced antibody iso-
type switching and increased production of IgG anti-HBcAg
antibodies. It was suggested recently that B cells that bind
capsids can prime cytotoxic T cells as well (Lazdina et al.,
2003). Finally, antigen presenting cells, other than B cells,
probably help to drive the response towards a Th1 phenotype
in euthymic mice. Non-specific uptake of capsids through
endocytosis or macropinocytosis releases the encapsidated
RNA. This results in a strong activation of the cells and
production of IL-12, a well-known strong inducer of Th1
immunity.
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